Vardenafil for the treatment of Raynaud phenomenon: A randomized, double-blind, placebo-controlled crossover study

Archives of Internal Medicine

Volumn 172, Issue 15, 2012, Pages 1182-1184

  Caglayan, Evren ^a   Axmann, Sarah ^a   Hellmich, Martin ^a   Moinzadeh, Pia ^a   Rosenkranz, Stephan ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; SILDENAFIL; TADALAFIL; VARDENAFIL;

ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DYSPEPSIA; FEMALE; FLUSHING; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; NASAL STUFFINESS; NOSE DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RAYNAUD PHENOMENON; SIDE EFFECT; VISUAL DISORDER;

DOUBLE-BLIND METHOD; DRUG MONITORING; FEMALE; FINGERS; HALF-LIFE; HUMANS; IMIDAZOLES; LASER-DOPPLER FLOWMETRY; MALE; PHOSPHODIESTERASE 5 INHIBITORS; PIPERAZINES; RAYNAUD DISEASE; REGIONAL BLOOD FLOW; SULFONES; TREATMENT OUTCOME; TRIAZINES;

EID: 84865682812     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinternmed.2012.2271     Document Type: Article

References (9)

1. De LaVega AJ, Derk CT. Phosphodiesterase-5 inhibitors for the treatment of Raynaud's: a novel indication. Expert Opin Investig Drugs. 2009;18(1):23-29.
2. Wigley FM. Clinical practice: Raynaud's phenomenon. NEngl J Med. 2002;347 (13):1001-1008.
3. Schiopu E, Hsu VM, Impens AJ, et al. Randomized placebo-controlled crossover trial of tadalafil in Raynaud's phenomenon secondary to systemic sclerosis. J Rheumatol. 2009;36(10):2264-2268.
4. Caglayan E, Huntgeburth M, Karasch T, et al. Phosphodiesterase type 5 inhibition is a novel therapeutic option in Raynaud disease. Arch Intern Med. 2006;166(2):231-233. (Pubitemid 43144949)
5. Fries R, Shariat K, von Wilmowsky H, BöhmM. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Circulation. 2005; 112(19):2980-2985. (Pubitemid 41612301)
6. Shenoy PD, Kumar S, Jha LK, et al. Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial. Rheumatology (Oxford). 2010;49(12):2420-2428.
7. Khanna PP, Maranian P, Gregory J, Khanna D. The minimally important difference and patient acceptable symptom state for the Raynaud's condition score in patients with Raynaud's phenomenon in a large randomised controlled clinical trial. Ann Rheum Dis. 2010;69(3):588-591.
8. Desouza C, Parulkar A, Lumpkin D, Akers D, Fonseca VA. Acute and prolonged effects of sildenafil on brachial artery flow-mediated dilatation in type 2 diabetes. Diabetes Care. 2002;25(8):1336-1339. (Pubitemid 41071142)
9. Friedman EA, Harris PA, Wood AJ, Stein CM, Kurnik D. The effects of tadalafil on cold-induced vasoconstriction in patientswith Raynaud's phenomenon. Clin Pharmacol Ther. 2007;81(4):503-509. (Pubitemid 46452307)